Experience

Argo Biopharma Announces Multi-Asset License and Option Agreements With Novartis

September 3, 2025

Cooley advised Argo Biopharma, a clinical-stage biotechnology company focused on developing next-generation small interfering RNA (siRNA) therapeutics, on its additional strategic collaboration with Novartis for multiple cardiovascular assets in Argo’s pipeline.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Freddy Yip
Associate, Hong Kong
Yuhan Wu
Associate, Palo Alto
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
Julia R. Brinton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Mari Dugas
Associate, Washington, DC
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Patrick Loofbourrow
Partner, Singapore
Phil Mitchell
Partner, New York
Bin Wang
Special Counsel, Palo Alto

Related Practices & Industries

Akeso Announces HK$3.97 Billion Placement of Shares

August 28, 2025

Cooley advised Akeso (Hong Kong Stock Exchange: 9926.HK), a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing and commercializing innovative medicines that address global medical needs, on its HK$3.97 billion (US$509.01 million) placement of shares.

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Yiying Wang
Counsel, Shanghai
Ying Liu
Associate, Hong Kong
April Wang
Associate, Hong Kong

Related Practices & Industries

Innogen Pharmaceutical Announces HK$682.87 Million IPO

August 15, 2025

Cooley advised Innogen Pharmaceutical on its HK$682.87 million initial public offering (IPO).

Read more

Related contacts

Ethan Jin
Partner, Beijing
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Mengchao Wu
Associate, Beijing
Hilda Li
Associate, Hong Kong
Yunxiang Xu
Associate, Shanghai
Jin Wang
Senior Legal Assistant, Beijing

Related Practices & Industries

Leads Biolabs Announces HK$1.29 Billion IPO

July 25, 2025

Cooley advised Nanjing Leads Biolabs Co. (Leads Biolabs), a clinical-stage biotechnology company that discovers, develops and commercializes new therapies in oncology, autoimmune and other severe diseases, on its HK$1.29 billion initial public offering (IPO).

Read more

Related contacts

Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Kaiting Yang
Counsel, Hong Kong
Yiying Wang
Counsel, Shanghai
Yunxiang Xu
Associate, Shanghai
Brian Lau
Associate, Hong Kong
Alex Wu
Associate, Shanghai
Daniel Zheng
Associate, Shanghai
Zhengyang Li
International Legal Project Manager, Hong Kong
Cindy Pan
International Legal Project Manager, Hong Kong
Zoe Wang
International Legal Project Manager, Shanghai
Xander Lee
Partner, Santa Monica
Francis Wheeler
Senior Counsel, Colorado
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Vince Sampson
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

DualityBio Announces HK$1.64 Billion IPO

April 24, 2025

Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Xander Lee
Partner, Santa Monica
Vince Sampson
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Monica Xu
Special Counsel, Shanghai
Hilda Li
Associate, Hong Kong
Zixiang Liu
Associate, Shanghai
Patrick Sharma
Associate, Santa Monica
Yiying Wang
Counsel, Shanghai
Yunxiang Xu
Associate, Shanghai
Kaiting Yang
Counsel, Hong Kong
Tonny Yu
Associate, Hong Kong
Tonny Yu
Associate, Hong Kong
Letian Wei
Legal Consultant, Shanghai
Cindy Pan
International Legal Project Manager, Hong Kong
Zoe Wang
International Legal Project Manager, Shanghai
Philip Kwan
Senior Legal Assistant, Hong Kong
Jin Wang
Senior Legal Assistant, Beijing

Related Practices & Industries

View more

Admissions and credentials

New York

Hong Kong (Registered Foreign Lawyer)

Rankings and accolades

Asian Legal Business (ALB): Thomson Reuters: Asia Dealmakers (2024)

China Business Law Journal (CBLJ) “The A-List” elite lawyers in China - Growth Driver (2023-2025)

The Legal 500 Asia Pacific - Leading Partner: Life Sciences and Healthcare in China (Foreign Firm) (2025)

Chambers and Partners Greater China - Up and Coming: Life Sciences in China (International Firm) (2025)

IFLR1000 Asia Pacific Rankings - Highly Regarded Lawyer: Capital Markets, M&A and Private Equity practices in China (Foreign Firm) (2024)

Asian Legal Business (ALB), Thomson Reuters: China Top 15 Capital Markets Lawyers (2022)

Asian Legal Business (ALB), Thomson Reuters: China Top 15 Rising Lawyers (2022)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.